Performance Comparison of Microfluidic and Immunomagnetic Platforms for Pancreatic CTC Enrichment
November 15, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
No Data Available.
Synonyms :
dexlansoprazole
Class :
Drugs for peptic ulcer & Proton pump inhibitors
Brand Name :
No Data Available.
Synonyms :
dexlansoprazole
Class :
Drugs for peptic ulcer & Proton pump inhibitors
30
mg
capsule
Orally
once a day
4 - 8
weeks
Duration can be modified according to symptom improvement in patients
Discontinuation of therapy every 6 to 12 months is recommended to avoid long-term therapy risk
Initial:
30
mg
Orally
once a day
8
weeks
Maintenance: If no improvements are seen in symptoms, increase the dose to 60 mg once a day after 4 weeks
Gastro Esophageal Reflux Disease (GERD)
For symptomatic non-erosive:
30
mg
Capsule
Orally
once a day
4
weeks
For erosive esophagitis with severe symptoms:
Initial: 60 mg orally once a day for 8 weeks
Maintenance: 30 mg orally once a day
Gastro Esophageal Reflux Disease (GERD)
Missed doses:
For missed doses, do not merge 2 doses at one time; take the next dose as scheduled by a physician
Dose Adjustments
30 mg orally once a day is recommended in case of moderate hepatic impairment
Terminate the therapy if severe hepatic impairment occurs
Gastroesophageal Reflux Disease (GERD)
30
mg
Orally
every day
4
weeks
Children > 12 years and adolescents::
60
mg
Capsule
Orally
once a day
8
weeks
Maintenance of healing: 30 mg orally once a day
Children and adolescents >16 years:
80
mg
Capsule
Orally
at bedtime
8
weeks
Gastro Esophageal Reflux Disease (GERD)
Children > 12 years and adolescents:
30
mg
Capsule
Orally
once a day
Dose Adjustments
• 30 mg orally once a day is recommended in case of moderate hepatic impairment
Terminate the therapy if severe hepatic impairment occurs
Gastroesophageal Reflux Disease (GERD)
Age: > 12 years:
30
mg
Orally
every day
4
weeks
when both drugs are combined, there may be a decrease in levels of serum concentration and absorption of erlotinib
may decrease the serum concentration
belumosudil: they may diminish the serum concentration of Inhibitors of the Proton Pump
may decrease the diagnostic effect of each other when combined
it may decrease the absorption of Levoketoconazole
may decrease the serum concentration
they decrease the concentration of active metabolites of infigratinib in the serum
may diminish the therapeutic effect of bisphosphonate derivative
may diminish the therapeutic effect of bisphosphonate derivative
may diminish the therapeutic effect of bisphosphonate derivative
may diminish the therapeutic effect of bisphosphonate derivative
may diminish the therapeutic effect of bisphosphonate derivatives
may diminish the therapeutic effect of bisphosphonate derivatives
may diminish the therapeutic effect of bisphosphonate derivatives
may diminish the therapeutic effect of bisphosphonate derivatives
may diminish the therapeutic effect of immune checkpoint inhibitors
may diminish the therapeutic effect of immune checkpoint inhibitors
may diminish the therapeutic effect of immune checkpoint inhibitors
Inhibitors of the Proton Pump: they may decrease the therapeutic effect of oral bisphosphonate derivatives
Inhibitors of the Proton Pump: they may decrease the therapeutic effect of oral bisphosphonate derivatives
Inhibitors of the Proton Pump: they may decrease the therapeutic effect of oral bisphosphonate derivatives
Inhibitors of the Proton Pump: they may decrease the therapeutic effect of oral bisphosphonate derivatives
Inhibitors of the Proton Pump: they may decrease the therapeutic effect of oral bisphosphonate derivatives
may enhance the concentration of serum when combined with dexlansoprazole
may enhance the concentration of serum when combined with dexlansoprazole
When dexrabeprazole and dexlansoprazole is used together, this leads to reduction in the dexrabeprazole’s metabolism
It may enhance the risk of adverse effects when combined with Proton pump inhibitors
It may enhance the risk of adverse effects when combined with Proton pump inhibitors
It may enhance the risk of adverse effects when combined with Proton pump inhibitors
When bacampicillin is combined with dexlansoprazole, bacampicillin absorption and blood levels decrease by stomach acid reduction.
when both drugs are combined, there may be an increased risk of hypomagnesemia
Proton Pump inhibitors may increase the absorption of amphetamine
it may decrease the serum concentration of Atazanavir
l-methylfolate-pyridoxal 5′-phosphate-methylcobalamine
it may decrease the serum concentration of Multivitamins
it may decrease the serum concentration of Minerals
it may decrease the serum concentration of Minerals
it may decrease the serum concentration of Minerals
it may decrease the serum concentration of Minerals
it may decrease the serum concentration of Minerals
may increase the serum concentration of itraconazole
they decrease the efficacy of cysteamine
This could lead to a reduction in concentration serum of mycophenolate
blessed thistle by pharmacodynamic antagonism decreases the effect of dexlansoprazole
by altering the gastrointestinal absorption, the concentration of cyanocobalamin may be reduced with dexlansoprazole
Action:
Dexlansoprazole is a proton pump inhibitor (PPI) that works by irreversibly binding to and inhibiting the H⁺/K⁺ ATPase enzyme system located on the surface of gastric parietal cells. This enzyme is responsible for the final step in the production of gastric acid. By blocking this pump, dexlansoprazole effectively suppresses both basal and stimulated acid secretion, leading to reduced gastric acidity.
Spectrum:
Dexlansoprazole is used to treat various acid-related gastrointestinal conditions. It is commonly prescribed for gastroesophageal reflux disease (GERD), including both erosive and non-erosive forms, where it helps reduce symptoms and prevent complications. It also promotes the healing of erosive esophagitis and helps maintain remission after healing. Additionally, dexlansoprazole provides effective relief from heartburn associated with GERD and is used in the prevention of acid-related mucosal damage caused by excessive gastric acid production.
Frequency defined:
1%-10%
Acute myocardial infraction
Arrhythmia
Chest pain
Bradycardia
Tachycardia
Skin lesion
Skin rash
Urticaria
Acne vulgaris
Dermatitis
Change in libido
Goiter
Hypokalemia
Heavy menstrual bleeding
Abdominal distress
Abdominal pain
Frequency not defined:
Increased serum creatinine
Agitation
Anaphylaxis
Decreased white blood cell
Disorientation
Hepatic fibrosis
Anxiety
Hallucination
Hemolytic anemia
Pancytopenia
Urinary retention
None
Contraindication:
Known hypersensitivity
Caution:
Hepatic impairment
Hypomagnesemia
Pregnancy and lactation
Gastric malignancy
Pregnancy consideration: No adverse effects have been reported in animal reproduction studies. It can be recommended for the treatment of GERD in pregnant women.
Lactation: Excretion of dexlansoprazole in breast milk is not known.
Pregnancy category:
Dexlansoprazole is a proton pump inhibitor (PPI) that works by selectively inhibiting the H⁺/K⁺-ATPase enzyme system at the surface of gastric parietal cells. This enzyme system is responsible for the final step in gastric acid production, and its inhibition leads to a significant and sustained reduction in gastric acid secretion
Pharmacokinetics:
Absorption
Dexlansoprazole exhibits a dual-release absorption pattern, with peak plasma concentrations occurring at approximately 1-2 hours and again at 4-5 hours post-administration.
Distribution
It is highly protein bound (>96%) and has a volume of distribution of 40.3 L.
Metabolism
The drug undergoes hepatic metabolism primarily through hydroxylation by CYP2C19 and oxidation to sulfone by CYP3A4.
Excretion and Elimination
Its elimination half-life ranges from 1 to 2 hours. Dexlansoprazole is excreted predominantly as metabolites, with approximately 51% eliminated in the urine and 48% in the feces.
Dexlansoprazole is administered orally and is available as a delayed-release capsule. It can be taken with or without food.
Patient information leaflet
Generic Name: dexlansoprazole
Pronounced: deks-lan-SOE-pra-zol
Why do we use dexlansoprazole?
Dexlansoprazole is a proton pump inhibitor (PPI) used to treat various acid-related gastrointestinal conditions. It is commonly prescribed for the treatment and maintenance of healing in erosive esophagitis and for the management of heartburn associated with gastroesophageal reflux disease (GERD), including both erosive and non-erosive forms. It helps reduce gastric acid secretion, thereby relieving symptoms such as heartburn, acid regurgitation, and discomfort caused by acid reflux.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
